Prime Medicine, Inc. Common Stock, Capital Shares Reserved for Future Issuance
Prime Medicine, Inc. (PRME) had Common Stock, Capital Shares Reserved for Future Issuance of 7.62 million shares as of 2022-12-31, per its 10-K filed 2023-03-09.
Discontinued › Notes › Stockholders' Equity Note › Class of Stock Disclosures
us-gaap:CommonStockCapitalSharesReservedForFutureIssuance · last filed 2023-03-09
- 2022-12-31: Common Stock, Capital Shares Reserved for Future Issuance 7.62M shares.
- 2022-09-30: Common Stock, Capital Shares Reserved for Future Issuance 57.29M shares.
- 2021-12-31: Common Stock, Capital Shares Reserved for Future Issuance 58.43M shares.
| Period end | Common Stock, Capital Shares Reserved for Future Issuance |
|---|---|
| 2022-12-31 | 7.62M shares 10-K · filed 2023-03-09 |
| 2022-09-30 | 57.29M shares 10-Q · filed 2022-11-14 |
| 2021-12-31 | 58.43M shares 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |